MedTrace Logo

A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis

NCT05890729 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 94

Last updated 2026-05-20

No results posted yet for this study

Summary

A phase 1b/2 study of XTMAB-16 in patients with pulmonary sarcoidosis

Conditions

  • Pulmonary Sarcoidosis

Interventions

DRUG

XTMAB-16 or Placebo

Infusion

Sponsors & Collaborators

  • Xentria, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-10
Primary Completion
2029-05-31
Completion
2029-05-31
FDA Drug
Yes

Countries

  • United States
  • Czechia
  • Denmark
  • Poland
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05890729 on ClinicalTrials.gov